INVENTIVA (EPA:IVA) | WebDisclosure

Basculer en Français

10942	Companies
239100	Keywords
167938	Articles
128547	Press releases

Home
Companies
INVENTIVA

PRESS RELEASE

published on 02/20/2025 at 22:00, 1 year 6 months ago

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Inventiva and Hepalys Pharma, Inc. initiate clinical development program of lanifibranor in Japan with dosing of first participant in Phase 1 trial, marking significant progress in partnership

Clinical Trial Japan Inventiva Lanifibranor Hepalys Pharma
BRIEF

published on 02/10/2025 at 22:05, 1 year 6 months ago

Inventiva annonce ses résultats financiers préliminaires pour 2024

Stratégie Résultats Financiers Financement Inventiva Lanifibranor
BRIEF

published on 02/10/2025 at 22:05, 1 year 6 months ago

Inventiva Announces Preliminary Financial Results for 2024

Financial Results Funding Strategy Inventiva Lanifibranor
PRESS RELEASE

published on 02/10/2025 at 22:00, 1 year 6 months ago

Inventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024¹ et fait le point sur son activité
Inventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024, met à jour son activité et annonce une réorganisation stratégique

Résultats Financiers Biopharmaceutique Reorganisation Inventiva Lanifibranor
PRESS RELEASE

published on 02/10/2025 at 22:00, 1 year 6 months ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Inventiva reports preliminary 2024 fiscal year financial results and business update, with €9.2 million revenues and €96.6 million cash as of December 31, 2024. Focused on lanifibranor development

Revenues Financial Results 2024 Fiscal Year Inventiva Lanifibranor
BRIEF

published on 01/24/2025 at 22:05, 1 year 7 months ago

Bilan semestriel du contrat de liquidité d'Inventiva avec Kepler Cheuvreux

Contrat De Liquidité Kepler Cheuvreux Biopharmaceutique Transactions Boursières Inventiva
BRIEF

published on 01/24/2025 at 22:05, 1 year 7 months ago

Half-yearly report on Inventiva's liquidity contract with Kepler Cheuvreux

Liquidity Contract Kepler Cheuvreux Biopharmaceutical Stock Market Transactions Inventiva
PRESS RELEASE

published on 01/24/2025 at 22:00, 1 year 7 months ago

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Inventiva publie son bilan semestriel du contrat de liquidité avec Kepler Cheuvreux. Espèces de 349 630,55 € et 113 452 actions Inventiva au 31/12/2024. Analyse des transactions du semestre. Entreprise biopharmaceutique axée sur la stéatohépatite et autres maladies

Contrat De Liquidité Bilan Semestriel Kepler Cheuvreux Biopharmaceutique Inventiva
PRESS RELEASE

published on 01/24/2025 at 22:00, 1 year 7 months ago

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inventiva announces half-year liquidity contract review with Kepler Cheuvreux. Cash and shares available in the liquidity account disclosed. Company focuses on developing oral small molecule therapies for MASH and unmet medical needs

Liquidity Contract Kepler Cheuvreux Clinical-Stage Biopharmaceutical Inventiva MASH
BRIEF

published on 01/22/2025 at 22:05, 1 year 7 months ago

Inventiva's LEGEND Trial Results to be Presented at EASL SLD Summit 2025

Lanifibranor Empagliflozin LEGEND Trial MASH Treatment EASL Summit 2025

Accesswire

Published on 09/08/2026 at 01:45, 7 hours 7 minutes ago

Tunkillia Environmental Scoping Report Approved
Published on 09/05/2026 at 04:05, 3 days 4 hours ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 3 days 9 hours ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 3 days 9 hours ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 3 days 10 hours ago

Panther Minerals Closes Brokered Private Placement of $3,000,000

View all ACCESSWIRE

EQS Group

Published on 09/08/2026 at 08:45, 7 minutes ago

innoscripta expands business in established Austrian market – order backlog exceeds EUR 1 million
Published on 09/08/2026 at 08:05, 47 minutes ago

New agentic AI platform sounds death knell for manual presentation tools
Published on 09/08/2026 at 08:05, 47 minutes ago

Autoliv Advances Vehicle Safety Through Virtual Testing
Published on 09/08/2026 at 08:05, 47 minutes ago

LX Pantos Successfully Completes Complex Defense Logistics Project for Advanced Weapons
Published on 09/08/2026 at 08:00, 52 minutes ago

Transfer of shares from treasury to the EBT and Total Voting Rights

Les Echos

Published on 09/08/2026 at 08:30, 22 minutes ago

Klarsen : calendrier de communication
Published on 09/07/2026 at 19:55, 12 hours 56 minutes ago

TFF GROUP CREE TFF UPCYCLING
Published on 09/07/2026 at 19:00, 13 hours 52 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 4 septembre 2026
Published on 09/07/2026 at 19:00, 13 hours 52 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 14 hours 47 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026

View all LES ECHOS COMFI WIRE